9/20/2021 8:25:32 AM
Mirati Therapeutics Announces Long-term Survival Results From Exploratory Analysis Of Sitravatinib Plus Nivolumab
9/20/2021 8:04:41 AM
Mirati Therapeutics Appoints David Meek As CEO
9/20/2021 7:32:23 AM
Mirati Therapeutics Announces Positive Topline Results From Phase 2 KRYSTAL-1 Study Evaluating Adagrasib
6/1/2021 7:46:27 AM
Mirati Therapeutics, Zai Lab Enter Collaboration To Develop Adagrasib In Greater China
6/1/2021 7:31:43 AM
Mirati Therapeutics And Zai Lab Collaborate To Develop Adagrasib In Greater China
3/31/2021 7:33:30 AM
Mirati Therapeutics Names Shalini Sharp New Independent Director
11/4/2016 7:23:37 AM
Wedbush Is Raising Mirati Therapeutics, Inc. (MRTX) Q4 17 Estimate To -0.81 From -0.98
11/4/2016 7:23:26 AM
Wedbush Is Raising Mirati Therapeutics, Inc. (MRTX) Q3 17 Estimate To -0.79 From -0.95
11/4/2016 7:23:16 AM
Wedbush Is Raising Mirati Therapeutics, Inc. (MRTX) Q2 17 Estimate To -0.77 From -0.93
11/4/2016 7:23:06 AM
Wedbush Is Increasing Mirati Therapeutics, Inc. (MRTX) Q1 17 Estimate To -0.76 From -0.91
11/4/2016 7:22:53 AM
Wedbush Is Raising Mirati Therapeutics, Inc. (MRTX) 2017 Estimate To -3.13 From -3.77
11/4/2016 7:22:36 AM
Wedbush Is Increasing Mirati Therapeutics, Inc. (MRTX) 2016 Estimate To -3.96 From -4.31
11/4/2016 7:22:23 AM
Wedbush Is Raising Mirati Therapeutics, Inc. (MRTX) Q4 16 Estimate To -0.75 From -0.90
11/4/2016 7:22:00 AM
Wedbush Reiterates Mirati Therapeutics, Inc. (MRTX) At Outperform With $12 Price Target
10/4/2016 12:00:42 PM
Wedbush Reiterates Mirati Therapeutics, Inc. (MRTX) At Outperform With $12 Price Target
5/6/2016 12:14:45 PM
Wedbush Reiterates Mirati Therapeutics, Inc. (MRTX) At Outperform With $41 Price Target
5/3/2016 11:44:06 AM
Wedbush Reiterates Mirati Therapeutics, Inc. (MRTX) At Outperform With $45 Price Target